Structure-guided evolution of antigenically distinct adeno-associated virus variants for immune evasion
- 30 May 2017
- journal article
- Published by Proceedings of the National Academy of Sciences in Proceedings of the National Academy of Sciences of the United States of America
- Vol. 114 (24), E4812-E4821
- https://doi.org/10.1073/pnas.1704766114
Abstract
Preexisting neutralizing antibodies (NAbs) against adeno-associated viruses (AAVs) pose a major, unresolved challenge that restricts patient enrollment in gene therapy clinical trials using recombinant AAV vectors. Structural studies suggest that despite a high degree of sequence variability, antibody recognition sites or antigenic hotspots on AAVs and other related parvoviruses might be evolutionarily conserved. To test this hypothesis, we developed a structure-guided evolution approach that does not require selective pressure exerted by NAbs. This strategy yielded highly divergent antigenic footprints that do not exist in natural AAV isolates. Specifically, synthetic variants obtained by evolving murine antigenic epitopes on an AAV serotype 1 capsid template can evade NAbs without compromising titer, transduction efficiency, or tissue tropism. One lead AAV variant generated by combining multiple evolved antigenic sites effectively evades polyclonal anti-AAV1 neutralizing sera from immunized mice and rhesus macaques. Furthermore, this variant displays robust immune evasion in nonhuman primate and human serum samples at dilution factors as high as 1:5, currently mandated by several clinical trials. Our results provide evidence that antibody recognition of AAV capsids is conserved across species. This approach can be applied to any AAV strain to evade NAbs in prospective patients for human gene therapy.Keywords
Funding Information
- HHS | NIH | National Heart, Lung, and Blood Institute (R01HL089221)
- HHS | NIH | National Heart, Lung, and Blood Institute (P01HL112761)
- HHS | NIH | National Institute of General Medical Sciences (R01GM082946)
- HHS | NIH | National Heart, Lung, and Blood Institute (R01HL089221)
- HHS | NIH | National Institute of General Medical Sciences (T32-GM008799)
This publication has 30 references indexed in Scilit:
- Characterization of the Adeno-Associated Virus 1 and 6 Sialic Acid Binding SiteJournal of Virology, 2016
- Prevalence of AAV1 neutralizing antibodies and consequences for a clinical trial of gene transfer for advanced heart failureGene Therapy, 2015
- In Silico Reconstruction of the Viral Evolutionary Lineage Yields a Potent Gene Therapy VectorCell Reports, 2015
- Prediction of adeno-associated virus neutralizing antibody activity for clinical applicationGene Therapy, 2015
- Adeno-Associated Virus at 50: A Golden Anniversary of Discovery, Research, and Gene Therapy Success—A Personal PerspectiveHuman Gene Therapy, 2015
- Adeno-Associated Virus Serotype 1 (AAV1)- and AAV5-Antibody Complex Structures Reveal Evolutionary Commonalities in Parvovirus Antigenic ReactivityJournal of Virology, 2015
- B-cell depletion is protective against anti-AAV capsid immune response: a human subject case studyMolecular Therapy - Methods & Clinical Development, 2014
- Capsid Antibodies to Different Adeno-Associated Virus Serotypes Bind Common RegionsJournal of Virology, 2013
- Development of AAV serotype-specific ELISAs using novel monoclonal antibodiesJournal of Virological Methods, 2007
- α2,3 and α2,6 N-Linked Sialic Acids Facilitate Efficient Binding and Transduction by Adeno-Associated Virus Types 1 and 6Journal of Virology, 2006